1	Infectious Complications in Philadelphia-Negative Adolescent and
2	Young Adult Acute Lymphoblastic Leukemia Patients in the Era of
3	Pediatric-Inspired Regimen
4	
5	Phoutthasin Vongngakesone <sup>1,2</sup> , Piangrawee Niprapan <sup>1</sup> , Sirichai Srichairatanakool <sup>1</sup> , Nonthakorn
6	Hantrakun <sup>1</sup> , Teerachat Punnachet <sup>1</sup> , Sasinee Hantrakool <sup>1</sup> , Pokpong Piriyakhuntorn <sup>1</sup> , Chatree
7	Chai-Adisaksopha <sup>1</sup> , Ekarat Rattarittamrong <sup>1</sup> , Adisak Tantiworawit <sup>1</sup> , Lalita Norasetthada <sup>1</sup> ,
8	Thanawat Rattanathammethee <sup>1</sup> *
9	
10	<sup>1</sup> Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai
11	University, Chiang Mai, Thailand
12	<sup>2</sup> Department of Internal Medicine, Setthathirath Hospital, Vientiane, Lao PDR
13	
14	*Corresponding author
15	Email: thanawat.r@cmu.ac.th (TR)
16	
17	
18	
19 20	
20 21	

## 22 Abstract

36

Introduction: Pediatric acute lymphoblastic leukemia (ALL) has cure rates exceeding 90%, while adult ALL has a 3-year survival rate of only 40–50%. Adolescents and young adults (AYAs) face unique challenges due to age-related factors and high-risk disease features. Although pediatricinspired regimens improve survival, intensive chemotherapy increases susceptibility to severe infections.

28 Methods: A retrospective analysis was conducted on AYA-ALL patients treated at Chiang Mai

29 University Hospital from 1 January 2007 to 31 December 2023. Patients were classified into

30 pediatric-inspired (TPOG) or adult regimens (Hyper-CVAD or GMALL). Infections were

31 categorized as clinically documented infections (CDI) or microbiologically documented

32 infections (MDI). Multivariate logistic regression was used to identify infection risk factors.

33 Results: Among 94 patients (62.8% male; median age 22.9 years), 56.4% received TPOG and

34 43.6% received adult regimens. Infectious complications occurred in 79.8% of patients, with

higher rates in the adult regimen group (90.2% vs. 71.7%, p = 0.03). CDI was more frequent in

37 TPOG group (26.4% vs. 9.8%, p = 0.04). Adult regimens significantly increased infection risk

the adult group (73.4% vs. 52.8%, p = 0.04), while fungal infections were more common in the

38 (OR 3.55; 95% CI 1.02–12.36, p = 0.04). Infection rates peaked during induction (47.8%) and

39 consolidation (51.8%). During induction, MDI was lower in the adult group (21% vs. 79%, p =

40 0.01), while CDI was higher during consolidation (69% vs. 30%, p < 0.01). Gram-negative

41 bacteria were the most common pathogens (85%), particularly *E. coli* (27%) and *Salmonella* spp.

42 (21%). Fungal infections affected 19.1% of patients, with invasive pulmonary aspergillosis being
43 the most common (11.7%).

44	<b>Conclusion:</b> AYA-ALL patients are highly susceptible to infections, especially those receiving				
45	adult regimens. Fungal infections were notably more common in patients on the TPOG regimen.				
46	Strengthening infection prevention and providing early treatment are vital for improving patient				
47	outcomes.				
48	Keywords: Acute lymphoblastic leukemia, Adolescents and young adults, Infectious				
49	complications, Pediatric-inspired regimen, microbiologically documented infections				
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					
61					
62					
63					
64					
65					
66					
67					
68					
69					

# 70 Introduction

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer but is relatively rare in adults, with an incidence of 1.7 cases per 100,000 annually in the total U.S. population [1]. Over the past few decades, the prognosis for pediatric ALL has significantly improved, with cure rates exceeding 90% using standard intensive multi-agent chemotherapy protocols [2, 3]. However, adult ALL remains associated with poorer outcomes, with only 40-50% survival at three years [4]. This survival gap is likely due to differences in disease biology, treatment response, and patientrelated factors.

Adolescents and young adults (AYAs), aged 15 to 39 years, face distinct treatment challenges due to their transitional physiology and a higher prevalence of high-risk disease features, resulting in event-free survival rates of 30-45% [5-7]. The presence of specific genetic factors, diversity within this age range, and different treatment protocols may contribute to the lower survival rates observed in adult ALL patients.

Multiple retrospective and prospective studies have demonstrated that pediatric-inspired regimens significantly improve survival outcomes in AYAs compared to standard adult regimens [8-10]. Despite improved survival, infections remain a significant cause of morbidity and mortality, particularly during induction therapy, affecting over 30% of patients. Bacterial infections accounted for nearly 70% of infection-related deaths, while fungal infections accounted for about 20% [11].

In Thailand, a study involving 107 ALL patients (67.3% received adult regimens and 32.7%
received pediatric-inspired regimens) found that patients treated with pediatric-inspired protocols
had better two-year disease-free survival (47.1% vs. 24.7%, hazard ratio [HR] 1.73, 95% CI 1.22–

92	3.03) and overall survival (50.8% vs. 31.2%, HR 1.52, 95% CI 0.83–2.78) compared to those
93	treated with adult regimens [12]. Similarly, a multi-centre prospective study showed that AYAs
94	had significantly higher two-year event-free survival compared to adults with ALL (45.5% vs
95	26.2%; P < 0.019) [13].

- 96 Despite evidence supporting pediatric-inspired regimens, the infection risks and associated factors
- 97 in AYAs with ALL remain understudied, particularly when comparing pediatric-inspired and adult
- 98 regimens in Thailand.

99

100 Methods

#### 101 Study design and Patients

102 This retrospective cohort study included newly diagnosed adolescent and young adult patients with 103 acute lymphoblastic leukemia (AYA-ALL), aged 15-40 years, treated at Chiang Mai University 104 Hospital between 1 January 2007 and 31 December 2023. The diagnosis was confirmed according 105 to the 2016 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues [14]. This 106 study followed the Declaration of Helsinki and the International Conference on Harmonization 107 Guidelines for Good Clinical Practice. The institutional ethical review board of the Faculty of 108 Medicine, Chiang Mai University, Thailand, approved the study (study code: MED-2566-0630). 109 Informed consent was waived due to the retrospective design and anonymized data collection. 110 Patients received induction chemotherapy using either a pediatric-inspired regimen (a modified 111 Thai Pediatric Oncology Group [TPOG] protocol) [12, 15], a dosage and intensity-adjusted

112 version of the Thai national childhood ALL protocol, or adult regimens (Hyper-CVAD or

113 GMALL) [16, 17]. Patients were excluded if they did not receive high-intensity chemotherapy, 114 had Philadelphia chromosome-positive ALL and/or the BCR::ABL1 fusion gene (detected via 115 polymerase chain reaction), had incomplete clinical records, received induction therapy prior to 116 referral, or had a known HIV infection. All patients received standard antimicrobial prophylaxis 117 with trimethoprim/sulfamethoxazole for *Pneumocystis jirovecii* pneumonia (PJP) and acyclovir 118 for herpes simplex virus (HSV) infections. Due to limited availability of mold-active antifungal 119 agents, fluconazole was used for fungal prophylaxis. However, fluconazole and 120 trimethoprim/sulfamethoxazole were withheld during certain treatment phases to prevent drug 121 interactions. Granulocyte colony-stimulating factor (G-CSF) was routinely administered during 122 induction and consolidation phases to reduce neutropenia-related infection risk. Notably, specific 123 data on antimicrobial prophylaxis regimens for bacterial, fungal, and viral infections were not 124 analyzed in this study.

#### 125 Data collection and outcomes

126 Clinical data were retrospectively collected from electronic medical records with de-identified 127 patients' data, potential bias from missing data. Data included baseline demographics, laboratory 128 results, infectious events, and treatment outcomes. Infectious complications during all 129 chemotherapy phases (induction, consolidation, and maintenance) were analyzed.

The primary outcome was the prevalence of infectious complications among AYA-ALL patients.
The secondary outcomes were to identify associated risk factors for infectious complications and
compare the infectious complications rate between patients receiving pediatric-inspired (TPOG)
and adult regimens (Hyper-CVAD or GMALL).

#### **135 Definitions of infectious complications**

- 136 Infectious complications were categorized as follows:
- Clinically Documented Infection (CDI): Clinical signs and symptoms of infection
   without an identifiable pathogen.
- Microbiologically Documented Infection (MDI): Isolation of a pathogen from blood
   cultures or other infection sites.
- 141 Fever was defined as a body temperature >38.3°C or a temperature >38°C persisting for at least 1
- hour. Febrile neutropenia was defined as fever with an absolute neutrophil count (ANC)  $< 500/\mu L$

143 [18].

#### 144 Sample size and statistical analysis

145 Based on previous studies [9, 10], an infection prevalence of 50% was assumed in AYA-ALL 146 patients. The required sample size was 97 patients, with a margin of error of 10% [19]. Continuous 147 variables were reported as mean with standard deviation (SD) or median with interquartile range 148 (IQR), depending on data distribution. Categorical variables were expressed as counts and 149 percentages. Group comparisons for categorical data were performed using the chi-square test or 150 Fisher's exact test. Continuous variables were compared using the Student's t-test or Mann-151 Whitney U test, as appropriate. Variables with a p-value < 0.1 in univariate analysis were entered 152 into a backward stepwise multivariate logistic regression model to identify independent risk factors 153 for infections. Results were reported as odds ratios (OR) and 95% confidence intervals (CI). 154 Statistical significance was set at p-value < 0.05. Patients with missing data were excluded. All

analyzes were performed using Microsoft Excel 2013 and STATA Version 17 (StataCorp, TX,
USA) software.

157

# 158 **Results**

#### 159 **Demographic and clinical characteristics**

160 A total of 124 newly diagnosed Philadelphia-negative ALL patients at Chiang Mai University 161 Hospital between 1 January 2007 and 31 December 2023 were retrospectively reviewed, 30 162 patients were excluded, and 94 AYA-ALL patients were recruited (Fig 1). The majority were male 163 (62.8%, n = 59), with a median age of 22.9 years (IQR 15-39.8). B-ALL was the most common 164 subtype (58.8%). Of these, 56.4% (n = 53) received pediatric-inspired TPOG regimen, while 165 43.6% (n = 41) received adult regimens (24 on Hyper-CVAD and 17 on GMALL). Overall, the 166 median follow-up was 14.3 months (IQR 7.5-30.9). Relapse or refractory disease occurred in 167 55.3% of patients, with a significantly higher rate in the adult regimen group compared to the 168 TPOG group (68.3 % vs. 45.3, p = 0.02). Only four patients (4.3%) underwent allogeneic stem cell 169 transplantation (AlloSCT). Baseline characteristics were summarized in Table 1.

170

Fig 1. Flow diagram demonstrated the recruitment alongside of inclusion and exclusion
criteria

173

Variables	All patients (n = 94)	TPOG (n = 53)	Adult regimen (n = 41)	<i>p</i> -value	
Age, years	22.9 (15-39.8)	23.8(15-39.2)	21.7 (15-39.8)	0.63	
Male, n (%)	59 (62.8)	36 (67.9)	23 (56.1)	0.24	
ALL subtype, n (%)				0.31	
B-ALL	55 (58.5)	31 (58.5)	24 (58.5)		
T-ALL	37 (39.4)	22 (41.5)	15 (36.6)		
N/A	2 (2.1)	0	2 (4.9)		
Hemoglobin, g/dL	9.5 (7.5-11.4)	9.5 (7.4-11.7)	9.1 (7.5-11.2)	0.60	
WBC, /µL	16600 (4500-47500)	23000 (5200-51400)	14170 (3570-39400)	0.40	
Platelet, /µL	75900 (32000-145000)	84000 (33000-158000)	65000 (32000-139000)	0.73	
Peripheral blood blasts, %	49.5 (4-83)	48 (4.7-85)	50 (3-82)	0.82	
Bone marrow blasts, %	90 (80-90)	90(80-90)	90(80-90)	0.12	
Induction death, n (%)	4 (4.2)	2 (3.8)	2 (4.8)	1	
Proceed to consolidation phase, n (%)	81 (86.1)	44 (83.0)	37 (90.2)	0.31	
Duration of consolidation, days	223 (93-313)	261.5 (109.5- 398.5)	199 (66-245)	< 0.01	
Proceed to maintenance phase, n (%)	31 (32.9)	18 (33.9)	13 (31.7)	0.81	
Duration of maintenance, days	721 (301-770)	731 (385-862)	516 (147-744)	0.16	
Completed maintenance phase, n (%)	16 (51.6)	10 (55.5)	6 (46.1)	0.72	
Relapse/Refractory, n (%)	52 (55.3)	24 (45.3)	28 (68.3)	0.02	
Allogeneic SCT, n (%)	4 (4.3)	3 (5.7)	1 (2.4)	0.62	

#### 175 Table 1. Demographic and clinical characteristics of AYA-ALL patients

As the continuous data in this study did not follow a normal distribution, all data were reported as medians with interquartile ranges (IQR). WBC: white blood cell count, SCT: stem cell transplantation

176

177

178

179

#### 181 Infectious outcomes

- 182 Infectious complications were reported in 79.8% (n = 75) of patients. Clinically documented
- 183 infections (CDI) occurred in 61.7% (n = 58), and microbiologically documented infections (MDI)
- in 55.3% (n = 52). Bacterial infections were the most common (44.6%, n = 42), followed by fungal
- 185 infections (19.1%, n = 18).
- 186 Patients on adult regimens experienced significantly more infectious complications than those on
- 187 the TPOG regimen (90.2% vs. 71.7%, p = 0.03), with higher CDI rates (73.4% vs. 52.8%, p =
- 188 0.04). Conversely, fungal infections were more frequent in the TPOG group (26.4% vs. 9.8%, p =

189 0.04) (Table 2).

190 Table 2. Infectious complications among AYA-ALL patients based on treatment regimens

Variables	All patients (n=94)	TPOG (n=53)	Adult regimen (n=41)	<i>p</i> -value
Overall infection, n (%)	75 (79.8)	38 (71.7)	37 (90.2)	0.03
CDI, n (%)	58 (61.7)	28 (52.8)	30 (73.2)	0.04
MDI, n (%)	52 (55.3)	28 (52.8)	24 (58.5)	0.58
Bacterial infection, n (%)	42 (44.6)	22 (41.5)	20 (48.8)	0.48
Fungus infection, n (%)	18 (19.1)	14 (26.4)	4 (9.8)	0.04

CDI: clinically documented infection, MDI: microbiologically documented infection

191

192 Infection rates peaked during induction (47.8%) and consolidation (51.8%). During consolidation,

193 infections were significantly higher in the adult regimen group compared to the TPOG group

194 (64.9% vs. 40.9%, p = 0.03) (Fig 2). MDI was most frequent in the TPOG group during induction

195 (79% vs. 21%, p = 0.01), whereas CDI was more common in the adult regimen group during the

196 consolidation (69% vs. 30%, p < 0.01) (S1 Table). Details of CDI based on treatment group and

197 phase of treatment were provided (S2 Table).

198	Fig 2. Number of infection based on treatment regimens and treatment phases
199	
200	S1 Table. Number and types of infectious episodes (CDI and MDI) based on treatment
201	regimens and treatment phases
202	
203	S2 Table. Clinically documented infection (CDI) based on treatment regimens and
204	treatment phases
205	
206	The most common infection sites for MDI were the bloodstream (40%), lung (24%) and the
207	genitourinary tract (16%) (S3 Table). Bacterial infections were the most prevalent (73%),
208	followed by fungal (24%) and viral (3%) infections. Gram-negative bacteria dominated (85%)
209	among bacterial pathogens, with E. coli (27%), Salmonella spp. (21%), and Klebsiella spp. (19%)
210	being the most prevalent. Aspergillus spp. was the most common fungal pathogen (S4 Table and
211	<b>S5 Table).</b> Induction-related mortality was $4.2\%$ (n = 4), with septicemia causing death in 2
212	patients and hemorrhagic complications in 2 patients.
213	S3 Table. Sites of microbiologically documented infection (MDI) based on treatment
214	regimens and treatment phases
215	S4 Table. Isolated pathogens of MDI in TPOG regimen group
216	S5 Table. Isolated pathogens of MDI in adult regimen group
217	
218	

## 219 **Risk factors for infectious complications**

Multivariate logistic regression identified treatment with an adult regimen as a significant risk factor for infectious complications among AYA-ALL patients (OR 3.55, 95% CI 1.02–12.36, p =0.04) (**Table 3**). For MDI, female sex (OR 3.88, 95% CI 1.41–10.68, p < 0.01) and platelet counts below 75,000 /µL (OR 3.41, 95% CI 1.33–8.74, p = 0.01) were independently associated with a higher risk. In contrast, patients younger than 23 years (OR 0.33, 95% CI 0.12–0.85, p = 0.02) and those receiving only first-line treatment (OR 0.36, 95% CI 0.13–0.93, p = 0.03) had a significantly lower risk of MDI (S6 Table).

227

		Univariate			Multivariate		
Variables	Variables		Non infection (n=19)	<i>p</i> -value	Odds ratio	95% CI	<i>p</i> -value
Treatment regimens	Adults	37 (90.2)	4 (9.8)	0.026	3.55	1.02-12.36	0.04
	TPOG	38 (71.7)	15 (28.3)				
Sex	Female	30 (85.7)	5 (14.3)	0.2			
	male	45 (76.3)	14 (23.7)				
ALL type	B cell	44 (80)	8 (20.5)	0.95			
	others	31 (79.5)	11 (20.0)				
Relapse	yes	44 (84.6)	8 (15.4)	0.19			
	no	31 (73.8)	11 (26.2)				
1 <sup>st</sup> line of treatment	yes	39 (72.2)	15 (27.8)	0.03	0.4	0.11-1.40	0.155
	no	36 (90)	4 (10)				
Age, years	< 23	37 (78.7)	10 (21.3)	0.79			
	>= 23	38 (80.8)	9 (19.1)				
WBC, /µL	<16600	40 (85.1)	7 (14.9)	0.19			

#### 228 Table 3. Univariate and multivariate analyses of risk factor for infectious complications

	>=16600	35 (74.5)	12 (25.5)				
Hb, g/dL	< 9.5	38 (80.9)	9 (19.1)	0.79			
	> = 9.5	37 (78.7)	10 (21.3)				
Platelet, /µL	<75000	39 (84.8)	7 (15.2)	0.23			
	>= 75000	36 (75.0)	12 (25.0)				
PB blasts, %	<50%	42 (89.4)	5 (10.6)	0.02	3.41	1.05-11.04	0.04
	>= 50%	33 (70.2)	14(29.8)				
BM blasts, %	<90%	34 (79.0)	9 (20.9)	0.87			
	>= 90%	41 (80.4)	10 (19.6)				

WBC: white blood cell count, Hb: hemoglobin, PB: peripheral blood, BM: bone marrow

229

#### 230 S6 Table. Univariate and multivariate analyses of risk factor for MDI

## 231 **Discussion**

This study demonstrated a high incidence of infectious complications in AYA-ALL patients, with 79.8% experiencing infections. Clinically documented infections (CDI) occurred in 61.7% of patients, and microbiologically documented infections (MDI) in 55.3%. These rates are comparable to studies from Taiwan and Mexico, which reported infection rates of approximately 87% in ALL patients receiving intensive chemotherapy [20, 21]. Similarly, an Italian study highlighted infectious complications as a leading cause of morbidity in AYA-ALL patients, underscoring the importance of infection prevention strategies [22].

## 239 Phase-specific infection risk

Infection rates were highest during the induction (47.8%) and consolidation (51.8%) phases,
aligning with findings from MD Anderson, which reported infection rates of 22% and 63% during

these phases, respectively [9]. The increased risk during induction is likely due to the intensive
chemotherapy and high-dose steroids, causing severe myelosuppression and immune suppression.
During consolidation, cumulative immunosuppression further elevates infection risk. Differences
in regimen intensity between TPOG and adult protocols may explain the observed variation in
infection rates, highlighting the need for phase-specific supportive care.

### 247 Fungal infection in the TPOG group

248 Fungal infections were more frequent in patients receiving the TPOG regimen (26.4%) compared 249 to those on adult regimens (9.8%), consistent with findings from Mexico, where 20% of ALL 250 patients developed fungal infections [21]. This increased risk in the TPOG group may result from 251 higher steroid doses and longer chemotherapy durations, which prolong immunosuppression and 252 impair both humoral and cellular immunity. Additionally, fluconazole was used for antifungal 253 prophylaxis due to limited access to mold-active agents at our center, potentially contributing to 254 the higher rates of Aspergillus infections. In contrast, studies from Saudi Arabia reported lower 255 fungal infection rates with micafungin or anidulafungin prophylaxis [23]. Environmental factors, 256 particularly in tropical climates, may also increase fungal exposure [24].

#### 257 Bacterial infections predominate in adult regimens

Gram-negative bacteria were the most common pathogens (85%), with *E. coli* (27%) and *Salmonella* spp. (21%) being the most prevalent. These findings align with studies from Italy, where gram-negative organisms were predominant in leukemia patients [25]. Patients on adult regimens experienced significantly more bacterial infections, likely due to prolonged and severe neutropenia associated with these protocols.

### 263 **Risk factors for infection**

Multivariate analysis identified treatment with adult regimens as a significant risk factor for overall infections (OR 3.55; p= 0.04). Female gender (OR 3.88; p < 0.01) and platelet counts below 75,000/µL (OR 3.41; p = 0.01) were independent risk factors for MDI. Conversely, younger patients (<23 years) and those receiving first-line treatment had a lower infection risk. The higher infection rate in females may be due to a higher incidence of urinary tract infections, as reported in other studies [20].

## 270 Clinical implications

These findings emphasize the need for tailored infection prevention strategies based on treatment regimen and phase. For patients receiving pediatric-inspired regimens, particularly TPOG, the use of mold-active antifungal prophylaxis should be considered. Patients on adult regimens may benefit from more aggressive bacterial infection prevention and early intervention during neutropenic episodes. Environmental and regional factors must also be considered when designing infection control protocols.

#### 277 Study limitations

This study has several limitations that should be considered when interpreting the findings. Its retrospective design may introduce selection bias, and incomplete or inconsistent medical records could affect data accuracy. The relatively small sample size and single-center setting limit the generalizability of the results to broader populations and other healthcare settings. Additionally, the study did not analyze antimicrobial resistance patterns, which could impact the interpretation of infection outcomes. Variations in antimicrobial prophylaxis regimens for bacterial, fungal, and

viral infections were also not fully assessed, potentially influencing infection rates. These limitations highlight the need for larger, multi-center prospective studies to validate these findings and optimize infection prevention strategies in AYA-ALL patients.

287

# 288 Conclusions

Our study highlights the high burden of infectious complications in AYA-ALL patients, particularly those receiving adult chemotherapy regimens. Fungal infections were notably more common in patients treated with pediatric-inspired regimens, likely due to prolonged steroid use and insufficient mold-active antifungal prophylaxis. These findings underscore the need for targeted infection prevention and early intervention strategies to improve outcomes in this vulnerable population.

295

## 296 Supporting information

- 297 **S1-6 File.** The table S1 to S6 (S1-6\_Table.docx)
- S1 Table. Number and types of infectious episodes (CDI and MDI) based on treatment regimensand treatment phases
- 300 S2 Table. Clinically documented infection (CDI) based on treatment regimens and treatment
   301 phases
- 302 S3 Table. Sites of microbiologically documented infection (MDI) based on treatment regimens
   303 and treatment phases

- 304 **S4 Table.** Isolated pathogens of MDI in TPOG regimen group
- 305 **S5 Table.** Isolated pathogens of MDI in adult regimen group
- 306 **S6 Table.** Univariate and multivariate analyses of risk factor for MDI

307

# 308 Acknowledgements

- 309 I would like to express my sincere gratitude to all the staff at the Division of Hematology,
- 310 Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, for their invaluable
- 311 support and dedication to patient care throughout this study.

# 312 **Conflict of Interest Statement**

313 The author(s) have declared that no potential conflicts of interest relevant to this article

# 314 Funding Sources

315 There was no funding in this study.

# 316 **Ethics Statement**

317 The study was conducted in accordance with the International Conference on Harmonization for

318 Good Clinical Practice guidelines and the 1964 Declaration of Helsinki. The study was approved

- 319 by the the institutional ethical review board of the Faculty of Medicine, Chiang Mai University,
- 320 Thailand (study code: MED-2566-0630). Informed consent was waived due to the retrospective
- 321 design and anonymized data collection.

# 323 Author's contributions:

- 324 Conceptualization: Thanawat Rattanathammethee
- 325 Methodology: Thanawat Rattanathammethee
- 326 Data curation: Thanawat Rattanathammethee, Phoutthasin Vongngakesone
- 327 Formal analysis: Thanawat Rattanathammethee, Phoutthasin Vongngakesone
- 328 Investigation: Thanawat Rattanathammethee, Phoutthasin Vongngakesone
- 329 Writing-Original draft: Thanawat Rattanathammethee, Phoutthasin Vongngakesone
- 330 Writing- review and editing: All authors
- 331

# 332 Data Availability Statement

333	The datasets generated during and/or analyzed in the current study, containing potentially
334	sensitive patient information and de-identified patient data, are available through the research
335	administration section of the Faculty of Medicine at Chiang Mai University, Thailand. (email:
336	researchmed@cmu.ac.th)
337	
338	
339	
340	
341	
342	
343	
344	

# 346 **References**

347 Surveillance, Epidemiology, and End Results Program (SEER) Cancer Stat Facts: 1. 348 Leukemia - Acute Lymphocytic leukemia (ALL). National Cancer Institute. Bethesda, MD 349 [Available from: https://seer.cancer.gov/statfacts/html/alyl.html]. Accessed 18 January 2025. 350 2. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What 351 determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia 352 treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and 353 Leukemia Group B studies. Blood. 2008;112(5):1646-54. 354 3. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 355 2015;373(16):1541-52. 356 4. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of 357 treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J 358 Clin Oncol. 2000;18(3):547-61. 359 5. Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and 360 young adults. Blood. 2015;125(24):3702-10. 361 6. Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc 362 Hematol Educ Program. 2018;2018(1):137-45. 363 7. Tran TH, Tasian SK. How I treat Philadelphia chromosome-like acute lymphoblastic 364 leukemia in children, adolescents, and young adults. Blood. 2025;145(1):20-34.

8. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M, Swedish Adult Acute
Lymphocytic Leukemia G, et al. Treatment outcome in young adults and children >10 years of

age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol andan adult protocol. Cancer. 2006;107(7):1551-61.

9. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, et al. Final
results of a single institution experience with a pediatric-based regimen, the augmented BerlinFrankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and
comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91(8):819-23.

373 10. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric
374 regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of
375 CALGB 10403. Blood. 2019;133(14):1548-59.

376 11. O'Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, et al. Infection-related mortality
377 in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
378 Blood. 2014;124(7):1056-61.

Tantiworawit A, Rattanathammethee T, Chai-Adisaksopha C, Rattarittamrong E,
Norasetthada L. Outcomes of adult acute lymphoblastic leukemia in the era of pediatric-inspired
regimens: a single-center experience. Int J Hematol. 2019;110(3):295-305.

13. Limvorapitak W, Owattanapanich W, Utchariyaprasit E, Niparuck P, Puavilai T,
Tantiworawit A, et al. Better survivals in adolescent and Young adults, compared to adults with
acute lymphoblastic leukemia - A multicenter prospective registry in Thai population. Leuk Res.
2019;87:106235.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016
revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Blood. 2016;127(20):2391-405.

389 15. Seksarn P, Wiangnon S, Veerakul G, Chotsampancharoen T, Kanjanapongkul S,
390 Chainansamit SO. Outcome of Childhood Acute Lymphoblastic Leukemia Treated Using the Thai
391 National Protocols. Asian Pac J Cancer Prev. 2015;16(11):4609-14.

392 16. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading
393 prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic
394 leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase
395 chain reaction analysis. Blood. 2002;99(5):1536-43.

Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up
results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone
(Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer.
2004;101(12):2788-801.

400 18. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice
401 guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by
402 the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93.

403 19. Naing L, Nordin RB, Abdul Rahman H, Naing YT. Sample size calculation for prevalence
404 studies using Scalex and ScalaR calculators. BMC Med Res Methodol. 2022;22(1):209.

Li MJ, Chang HH, Yang YL, Lu MY, Shao PL, Fu CM, et al. Infectious complications in
children with acute lymphoblastic leukemia treated with the Taiwan Pediatric Oncology Group
protocol: A 16-year tertiary single-institution experience. Pediatr Blood Cancer. 2017;64(10).

408 21. Inclan-Alarcon SI, Riviello-Goya S, Teran-De-la-Sancha K, Fierro-Angulo OM, Acosta-

409 Medina AA, Demichelis-Gomez R, et al. Induction-related mortality in adolescents and young


410	adults with acute lymphoblastic leukemia in a resource-limited setting: do treatment-related
411	complications create more impact than disease biology? Blood Res. 2022;57(1):29-33.
412	22. Zappasodi P, Calabretta L, Lazzarotto D, Cerrano M, Fracchiolla N, Papayannidis C, et al.
413	Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic
414	Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol. Blood.
415	2023;142(Supplement 1):5877
416	23. Salama H, Eldadah S, Omer MH, Alhejazi A, Bin Dayil L, Almozaini A, et al. Comparison
417	of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults

418 with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.


419 Leuk Res. 2023;130:107316.

420 24. Tang JL, Kung HC, Lei WC, Yao M, Wu UI, Hsu SC, et al. High Incidences of Invasive
421 Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy
422 without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. PLoS
423 One. 2015;10(6):e0128410.

424 25. Offidani M, Corvatta L, Malerba L, Marconi M, Leoni P. Infectious complications in adult
425 acute lymphoblastic leukemia (ALL): experience at one single center. Leuk Lymphoma.
426 2004;45(8):1617-21.



124 newly diagnosed Philadelphia-negative ALL patients (1 January 2007 to 31 December 2023)



94 Philadelphia-negative AYA-ALL patients met inclusion criteria

# Figure1